These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

409 related articles for article (PubMed ID: 29189354)

  • 1. Probiotics for prevention of Clostridium difficile infection.
    Mills JP; Rao K; Young VB
    Curr Opin Gastroenterol; 2018 Jan; 34(1):3-10. PubMed ID: 29189354
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Probiotics in clostridium difficile Infection.
    Na X; Kelly C
    J Clin Gastroenterol; 2011 Nov; 45 Suppl(Suppl):S154-8. PubMed ID: 21992956
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevention of Clostridium difficile Infection With Probiotics.
    Evans CT; Johnson S
    Clin Infect Dis; 2015 May; 60 Suppl 2():S122-8. PubMed ID: 25922397
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clostridium difficile Colitis Prevention and Treatment.
    Dinleyici M; Vandenplas Y
    Adv Exp Med Biol; 2019; 1125():139-146. PubMed ID: 30689174
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Probiotics and Fecal Microbiota Transplant for Primary and Secondary Prevention of Clostridium difficile Infection.
    Crow JR; Davis SL; Chaykosky DM; Smith TT; Smith JM
    Pharmacotherapy; 2015 Nov; 35(11):1016-25. PubMed ID: 26598094
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Navigating changes in
    Durham SH; Le P; Cassano AT
    J Manag Care Spec Pharm; 2020 Dec; 26(12-a Suppl):S3-S23. PubMed ID: 33533699
    [No Abstract]   [Full Text] [Related]  

  • 7. Prevention of recurrent Clostridioides difficile infection: A systematic review of randomized controlled trials.
    Madoff SE; Urquiaga M; Alonso CD; Kelly CP
    Anaerobe; 2020 Feb; 61():102098. PubMed ID: 31493500
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and Safety of RBX2660 in PUNCH CD3, a Phase III, Randomized, Double-Blind, Placebo-Controlled Trial with a Bayesian Primary Analysis for the Prevention of Recurrent Clostridioides difficile Infection.
    Khanna S; Assi M; Lee C; Yoho D; Louie T; Knapple W; Aguilar H; Garcia-Diaz J; Wang GP; Berry SM; Marion J; Su X; Braun T; Bancke L; Feuerstadt P
    Drugs; 2022 Oct; 82(15):1527-1538. PubMed ID: 36287379
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Primary prevention of Clostridium difficile infections with a specific probiotic combining Lactobacillus acidophilus, L. casei, and L. rhamnosus strains: assessing the evidence.
    McFarland LV; Ship N; Auclair J; Millette M
    J Hosp Infect; 2018 Aug; 99(4):443-452. PubMed ID: 29702133
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Successful therapy of Clostridium difficile infection with fecal microbiota transplantation.
    Konturek PC; Koziel J; Dieterich W; Haziri D; Wirtz S; Glowczyk I; Konturek K; Neurath MF; Zopf Y
    J Physiol Pharmacol; 2016 Dec; 67(6):859-866. PubMed ID: 28195066
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fecal microbiota transplantation for relapsing Clostridium difficile infection in 26 patients: methodology and results.
    Kelly CR; de Leon L; Jasutkar N
    J Clin Gastroenterol; 2012 Feb; 46(2):145-9. PubMed ID: 22157239
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The fascination with probiotics for Clostridium difficile infection: lack of evidence for prophylactic or therapeutic efficacy.
    Miller M
    Anaerobe; 2009 Dec; 15(6):281-4. PubMed ID: 19699309
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The potential of microbiome replacement therapies for Clostridium difficile infection.
    Buckley AM; Moura IB; Wilcox MH
    Curr Opin Gastroenterol; 2022 Jan; 38(1):1-6. PubMed ID: 34871192
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fecal Microbiota Transplantation and Medical Therapy for Clostridium difficile Infection : Meta-analysis of Randomized Controlled Trials.
    Singh T; Bedi P; Bumrah K; Gandhi D; Arora T; Verma N; Schleicher M; Rai MP; Garg R; Verma B; Sanaka MR
    J Clin Gastroenterol; 2022 Nov-Dec 01; 56(10):881-888. PubMed ID: 34516460
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fecal microbiota transplantation for the treatment of Clostridium difficile infection.
    Rao K; Safdar N
    J Hosp Med; 2016 Jan; 11(1):56-61. PubMed ID: 26344412
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The mechanisms and safety of probiotics against toxigenic
    Liu D; Zeng L; Yan Z; Jia J; Gao J; Wei Y
    Expert Rev Anti Infect Ther; 2020 Oct; 18(10):967-975. PubMed ID: 32520637
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Next-Generation Probiotics Targeting Clostridium difficile through Precursor-Directed Antimicrobial Biosynthesis.
    Spinler JK; Auchtung J; Brown A; Boonma P; Oezguen N; Ross CL; Luna RA; Runge J; Versalovic J; Peniche A; Dann SM; Britton RA; Haag A; Savidge TC
    Infect Immun; 2017 Oct; 85(10):. PubMed ID: 28760934
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Microbiota transplantation restores normal fecal bile acid composition in recurrent Clostridium difficile infection.
    Weingarden AR; Chen C; Bobr A; Yao D; Lu Y; Nelson VM; Sadowsky MJ; Khoruts A
    Am J Physiol Gastrointest Liver Physiol; 2014 Feb; 306(4):G310-9. PubMed ID: 24284963
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clostridium difficile infection: A brief update on emerging therapies.
    Goldberg EJ; Bhalodia S; Jacob S; Patel H; Trinh KV; Varghese B; Yang J; Young SR; Raffa RB
    Am J Health Syst Pharm; 2015 Jun; 72(12):1007-12. PubMed ID: 26025991
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evidence-based review of probiotics for antibiotic-associated diarrhea and Clostridium difficile infections.
    McFarland LV
    Anaerobe; 2009 Dec; 15(6):274-80. PubMed ID: 19825425
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.